GlobeNewswire

eGain announces webcast that features analyst on AI-powered digital transformation

Del

Thought leadership webcast features Gartner analyst, covers sweeping trends and approaches to making digital experience transformation successful

SUNNYVALE, Calif., and NEWBURY, United Kingdom, Feb. 27, 2018 (GLOBE NEWSWIRE) --  eGain (Nasdaq:EGAN), the leading provider of cloud customer engagement solutions, today announced the immediate availability of a thought leadership webcast on digital transformation.

According to statistics, 70%-90% of digital transformation projects fail. In this webcast, Brian Manusama, Research Director at Gartner, and Ashu Roy, eGain CEO, talk about the big trends in digital experience (DX), and how a holistic approach that balances all the elements of the experience triad-agent (AX), business (BX), and customer (CX)-can lead to DX success. In addition, Mr. Roy talks about how eGain makes DX easy with digital-first, omnichannel engagement tools, powered by AI, knowledge, and analytics - across customer journeys and contact center operations. Also included are client examples and a risk-free approach to DX innovation consumption.

More information
Title: 
Reinvent Agent, Business, and Customer Experience to Transform Digital Experience: 
AX+BX+CX = DX
Where to find: http://bit.ly/2oeiakK
Related material: Ashu Roy keynote at eGain Digital+AI Day 2017

About eGain

eGain customer engagement solutions power digital transformation for leading brands. Our top-rated cloud applications for social, mobile, web, and contact centers help clients deliver connected customer journeys in an omnichannel world. To find out more about eGain, visit http://www.egain.com.

eGain, the eGain logo, and all other eGain product names and slogans are trademarks or registered trademarks of eGain Corp. in the United States and/or other countries. All other company names and products mentioned in this release may be trademarks or registered trademarks of the respective companies.

Media contact                              

Tim Cox
ZingPR on behalf of eGain
Tim@ZingPR.com

Jane Stewart
eGain Europe
Email: press@egain.com
Phone: +44 (0)1635 800087, Ext. 5118




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: eGain Corporation via Globenewswire

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

ProQR Announces Publication in Nature Medicine of QR-110 Data for Leber’s Congenital Amaurosis 1017.12.2018 17:52Pressemelding

LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the publication of a peer-reviewed manuscript describing the previously announced interim results of a clinical trial of QR-110 for the treatment of Leber’s congenital amaurosis 10 (LCA10) in the journal Nature Medicine. “It was enormously gratifying to see robust improvements in visual acuity and significant augmentations in the patient’s ability to detect lights, and impressive to observe these effects within the first three months following a single injection,” said Professor Artur V. Cideciyan, Ph.D., who was one of the co-investigators at the Scheie Eye Institute of the University of Pennsylvania. “LCA10 is a severe form of childhood blindness and this is a major step forward in the treatment of these previously

Allied Esports™ Announces Formation of World’s First Affiliate Program for Esports Venues17.12.2018 15:30Pressemelding

Allied Esports™ Property Network to Offer Members Access to Global Events and Content, Expertise in Design and Operations, and Unique Sponsorship OpportunitiesFortress Esports Joins Program with Partnership Covering Exclusive Rights to New Properties in Australia and New Zealand ORANGE COUNTY, Calif., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Allied Esports™, a global esports entertainment company, today announced the formation of the world’s first esports venue affiliate program – the Allied Esports Property Network – created for global partners interested in participating in Allied Esports’ global event programming, and licensing Allied Esports’ design, development and operations expertise for their own dedicated esports venues. The Allied Esports Property Network will provide members with access to Allied Esports’ global platform of events and content production, providing participants and viewers with integrated experiences both in-person and online. Affiliate members will be fully incorpo

Aryaka Names Cloud and Software Industry Veteran, Deepak Kumar, as Senior Vice President of Customer Success17.12.2018 15:00Pressemelding

SAN MATEO, Calif., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Aryaka®, the leading SD-WAN as a Service provider, announced today that Deepak Kumar, a 20-year cloud and enterprise software industry veteran, has joined the company’s leadership team as Senior Vice President, Customer Success. "We’re thrilled to welcome Deepak to Aryaka; his leadership will help us further enhance our end-user customer experience worldwide,” said Matt Carter, CEO of Aryaka. “His expertise in building and nurturing enterprise relationships will be critical as we continue to grow in 2019 and beyond.” Before joining Aryaka, Kumar was the SVP & GM at [24]7.ai, a Sequoia portfolio company in the customer experience domain. As SVP Business Development, he was responsible for building out strategic partnerships and alliances. His hard work grew the channel driven revenue significantly. As General Manager, Kumar was responsible for the Customer Acquisition Cloud product line. The product line was built based on strategic a

Biome Grow receives new consumer sales amendment from Health Canada for its Nova Scotia brand, Highland Grow17.12.2018 14:00Pressemelding

Sales amendment granted for Highland Grow—Amendment to License Significantly Increases Product Availability for Medical and Adult Consumer-Use Markets TORONTO, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Biome Grow Inc. (“Biome” or the “Company”) (CSE: BIO) (Frankfurt: 6OTA) (OTC: ORTFF) is pleased to announce its Nova Scotia-based subsidiary, Highland Grow Inc. (“Highland Grow”), has received its sales authorization via an amendment to its existing license from Health Canada under the Cannabis Act. This authorization will allow Highland Grow to sell cannabis products to end consumers through appropriate medical and recreational cannabis channels, dramatically increasing product availability. The sales authorization will position Biome Grow to serve the rapidly growing domestic and international cannabis markets. "Biome Grow has been steadfast in its focus on a regional business strategy and building provincial brands that can serve the unique requirements of its local cannabis consumers. This n

Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis17.12.2018 13:30Pressemelding

DUBLIN, Ireland and CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: BIIB) today announced that Alkermes has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for diroximel fumarate (BIIB098), a novel oral fumarate in development for the treatment of relapsing forms of multiple sclerosis (MS). Alkermes is seeking approval of diroximel fumarate under the 505(b)(2) regulatory pathway, and the NDA submission includes data from EVOLVE-1, a Phase 3 pivotal trial that evaluated long-term safety in relapsing-remitting MS (RRMS) with approximately 700 patients dosed with diroximel fumarate. If approved, Biogen intends to market diroximel fumarate under the brand name VUMERITY™. This name has been conditionally accepted by the FDA and will be confirmed upon approval. “Diroximel fumarate was designed to provide patients with relapsing forms of multiple sclerosis a novel oral fumarate with a differentiated

SoftServe Documentary Receives “The Best Corporate Media of Ukraine 2018” Award17.12.2018 13:00Pressemelding

25th anniversary documentary takes prize in “The Best Corporate Movie” category AUSTIN, Texas, Dec. 17, 2018 (GLOBE NEWSWIRE) -- SoftServe, a leading digital authority and consulting company, announces the Ukrainian Association of Corporate Media, a public organization uniting professionals in the field of marketing, PR, journalism, and advertising, recognized SoftServe in its annual competition – “The Best Corporate Media of Ukraine 2018.” SoftServe’s 25th anniversary documentary took second place in the “The Best Corporate Movie Category.” The documentary honors the company’s 25th anniversary with an inside look at how SoftServe evolved over the past quarter century to become a leading digital authority. In the documentary, SoftServe’s founders and leadership share their inspiring stories and highlight the company’s achievements over the years. “It is a great honor to receive this recognition from the Ukrainian Association of Corporate Media for our 25th anniversary documentary,” sai